𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Oral adjuvant chemotherapy with Carmofur (HCFU) for colorectal cancer: Five-year follow-up. Tokai HCFU Study Group—third study on colorectal cancer

✍ Scribed by Ito, Katsuki; Yamaguchi, Akihiro; Miura, Kaoru; Kato, Tomoyuki; Baba, Shozo; Matsumoto, Sumio; Ishii, Masataka; Takagi, Hiroshi

Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
393 KB
Volume
63
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

✦ Synopsis

Background:

A joint study was performed by the tokai hcfu study group, which included seven institutions, to examine the value of oral administration of carmofur (hcfu), a 5-fluorouracil (5-fu) derivative, for postoperative adjuvant chemotherapy in patients with colorectal cancer undergoing curative resection.

Methods:

The patients were divided into two groups, a control group receiving no hcfu and a group administered hcfu for 1 year, using a centralized registration system by telephone. among 173 patients entered into this study, 159 evaluable cases were analyzed for evaluation of the drug.

Results:

The cumulative 5-year disease-free rate of patients who received hcfu was significantly increased compared with the control group. in particular, the rate was much higher in patients with colon cancer. no severe side effects arose from adjuvant chemotherapy with hcfu.

Conclusion:

Adjuvant chemotherapy with oral hcfu appears to provide a useful and safe postoperative treatment.

📜 SIMILAR VOLUMES

Prospective adjuvant therapy with Mitomy
Prospective adjuvant therapy with Mitomycin C and Carmofur (HCFU) for colorectal cancer, 10-year follow-up: Tokai HCFU Study Group, the first study for colorectal cancer
✍ Ito, Katsuki; Yamaguchi, Akihiro; Miura, Kaoru; Kato, Tomoyuki; Koike, Akihiko; 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 466 KB 👁 1 views

A joint study was performed by the Tokai HCFU study group, which included 41 institutions to study the usefulness of the concomitant therapy with Mitomycin C (MMC) and Carmofur (HCFU) as a postoperative adjuvant chemotherapy in patients with colorectal cancer who had curative resection. Patients wer

Prognostic factors for patients with col
Prognostic factors for patients with colon or rectal carcinoma treated with resection only: Five-year follow-up report
✍ Takeshi Tominaga; Takashi Sakabe; Yasuo Koyama; Kyoichi Hamano; Masayuki Yasutom 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 488 KB 👁 2 views

## BACKGROUND. The prognostic factors and natural history of recurrence in patients with colorectal carcinoma who underwent curative resection and no other therapy were analyzed. METHODS. The object of analysis was the potentially curative resection only subgroup in the randomized clinical trial (R